Back to Authors

Alkhateeb, Hassan B.

https://orcid.org/0000-0002-3609-8404

A5064856519 | I1330342723

Mayo Clinic

Citations 270

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859

Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6309-6311

10.1182/blood-2022-164769

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9019-9020

10.1182/blood-2022-168303

CAR-T Prescriber Preferences in Adolescents and Young Adults with B-ALL

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12762-12763

10.1182/blood-2022-163390

Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1286-1287

10.1182/blood-2022-165491

Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10942-10944

10.1182/blood-2022-164785

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12238-12240

10.1182/blood-2022-165470

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9735-9736

10.1182/blood-2022-163450

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6962-6963

10.1182/blood-2022-167978

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6964-6965

10.1182/blood-2022-168349